Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer

Masafumi Nakamura, Tadashi Kayashima, Kenji Fujiwara, Yosuke Nagayoshi, Hiroshi Kono, Takao Ohtsuka, Shunichi Takahata, Kazuhiro Mizumoto, Masao Tanaka

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Background/Aims: Although adjuvant chemotherapy (AC) using gemcitabine improves the prognosis of patients with resectable pancreatic cancer, the effect of gemcitabine AC on the prognosis of patients with borderline resectable pancreatic cancer is not clear. Methodology: We analyzed the prognosis of patients with pancreatic cancer who underwent curative pancreatoduodenectomy or total pancreatectomy in combination with portal/superior mesenteric vein resection (PVR) [PVR (+) group] or without PVR [PVR(-) group]. Results: MST of the PVR (+) group was significantly shorter than that of the PVR(-) group (p=0.017). In contrast, when we focused on the patients with gemcitabine AC, there was no significant difference in MST between the PVR (+) and the PVR (-) groups (p=0.247]. Furthermore, we compared MST of two subgroups in the PVR (+) group depending on gemcitabine AC status. In the PVR (+) group, MST of the patients with gemcitabine AC was significantly longer than that without gemcitabine AC (p=0.003). This was also true for the patients with pancreatic cancer which had histologically proven invasion to portal/superior mesenteric vein (PV/SMV) (p=0.001). Conclusions: The prognosis of patients with pancreatic cancer invading PV/SMV can be improved by combination therapy with PVR and gemcitabine adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)354-357
Number of pages4
JournalHepato-gastroenterology
Volume60
Issue number121
DOIs
Publication statusPublished - Jan 2013

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this